Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Photo

FDA Clears Uptravi (Selexipag) for Pulmonary Arterial Hypertension.

pah treatments

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,616 posts
  • Location:West Sussex

Posted 09 March 2016 - 06:32 AM

FDA Clears Uptravi (Selexipag) for Pulmonary Arterial Hypertension.

 

Uptravi (Selexipag) was shown to be effective in reducing hospitalization for PAH and reducing the risks of disease progression compared to placebo. FDA, 12/22/2015. (Also see Treatments for Pulmonary Hypertension)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)